全文获取类型
收费全文 | 9256篇 |
免费 | 832篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 114篇 |
儿科学 | 308篇 |
妇产科学 | 218篇 |
基础医学 | 1428篇 |
口腔科学 | 245篇 |
临床医学 | 771篇 |
内科学 | 2062篇 |
皮肤病学 | 244篇 |
神经病学 | 961篇 |
特种医学 | 300篇 |
外国民族医学 | 1篇 |
外科学 | 1315篇 |
综合类 | 45篇 |
一般理论 | 1篇 |
预防医学 | 711篇 |
眼科学 | 131篇 |
药学 | 619篇 |
中国医学 | 19篇 |
肿瘤学 | 637篇 |
出版年
2023年 | 52篇 |
2022年 | 115篇 |
2021年 | 235篇 |
2020年 | 154篇 |
2019年 | 243篇 |
2018年 | 306篇 |
2017年 | 212篇 |
2016年 | 234篇 |
2015年 | 244篇 |
2014年 | 299篇 |
2013年 | 416篇 |
2012年 | 536篇 |
2011年 | 537篇 |
2010年 | 336篇 |
2009年 | 264篇 |
2008年 | 425篇 |
2007年 | 428篇 |
2006年 | 453篇 |
2005年 | 408篇 |
2004年 | 374篇 |
2003年 | 309篇 |
2002年 | 324篇 |
2001年 | 315篇 |
2000年 | 302篇 |
1999年 | 250篇 |
1998年 | 94篇 |
1997年 | 98篇 |
1996年 | 82篇 |
1995年 | 95篇 |
1994年 | 68篇 |
1993年 | 48篇 |
1992年 | 204篇 |
1991年 | 176篇 |
1990年 | 162篇 |
1989年 | 163篇 |
1988年 | 146篇 |
1987年 | 112篇 |
1986年 | 107篇 |
1985年 | 105篇 |
1984年 | 94篇 |
1983年 | 59篇 |
1982年 | 40篇 |
1981年 | 30篇 |
1980年 | 32篇 |
1979年 | 60篇 |
1978年 | 32篇 |
1976年 | 29篇 |
1974年 | 40篇 |
1973年 | 34篇 |
1971年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
971.
972.
Faiez Zannad Jacqueline Alikhaani Sadegh Alikhaani Javed Butler Jason Gordon Klaus Jensen Rani Khatib Lorenzo Mantovani Robin Martinez Wanda F. Moore Masahiro Murakami Lothar Roessig Norman Stockbridge Harriette G.C. Van Spall Clyde Yancy John A. Spertus 《European journal of heart failure》2023,25(4):478-487
There are many consequences of heart failure (HF), including symptoms, impaired health-related quality of life (HRQoL), and physical and social limitations (functional status). These have a substantial impact on patients' lives, yet are not routinely captured in clinical trials. Patient-reported outcomes (PROs) can quantify patients' experiences of their disease and its treatment. Steps can be taken to improve the use of PROs in HF trials, in regulatory and payer decisions, and in patient care. Importantly, PRO measures (PROMs) must be developed with involvement of patients, family members, and caregivers from diverse demographic groups and communities. PRO data collection should become more routine not only in clinical trials but also in clinical practice. This may be facilitated by the use of digital tools and interdisciplinary patient advocacy efforts. There is a need for standardization, not only of the PROM instruments, but also in procedures for analysis, interpretation and reporting PRO data. More work needs to be done to determine the degree of change that is important to patients and that is associated with increased risks of clinical events. This ‘minimal clinically important difference’ requires further research to determine thresholds for different PROMs, to assess consistency across trial populations, and to define standards for improvement that warrant regulatory and reimbursement approvals. PROs are a vital part of patient care and drug development, and more work should be done to ensure that these measures are both reflective of the patient experience and that they are more widely employed. 相似文献
973.
Maria Pabon Brian L. Claggett Xiaowen Wang Zi Michael Miao Safia Chatur Ankeet S. Bhatt Muthiah Vaduganathan James C. Fang Akshay S Desai Pardeep Jhund Felipe Martinez Rudolf A. de Boer Mikhail N. Kosiborod Carolyn S.P. Lam Sanjiv J. Shah Adrian F. Hernandez John J.V. McMurray Scott D. Solomon Orly Vardeny 《European journal of heart failure》2023,25(9):1663-1670
Aims
The Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial demonstrated the sodium–glucose cotransporter 2 inhibitor dapagliflozin to be beneficial in patients with symptomatic heart failure (HF) with improved ejection fraction (HFimpEF; those with prior left ventricular ejection fraction ≤40% that had improved to >40% by enrolment). Whether this benefit differs by background medical therapy is unclear. The current study aims to determine the efficacy and safety of dapagliflozin among patients with HFimpEF by background medical therapy.Methods and results
Treatment effects on the primary endpoint (worsening HF or cardiovascular death) were assessed by number of background HF medical therapies (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor–neprilysin inhibitor, evidence-based beta-blocker, and mineralocorticoid receptor antagonist). Among the 6263 patients randomized in DELIVER, 1151 (18%) had HFimpEF. Of those, 21% of patients were on 0–1 therapies, 44% were on two therapies, and 35% were on three therapies. During 2.3 years of median follow-up, the incidence rate of the primary outcome was 9.7, 8.8, and 8.4 per 100 person-years for patients on 0–1, 2 and 3 HF medications at baseline, respectively. Treatment effects with dapagliflozin on the primary outcome may be greater in patients with HFimpEF on 0–1 therapies at baseline (pinteraction = 0.09), driven mostly by a significant interaction for HF hospitalization (pinteraction = 0.023) with no evidence of effect modification for cardiovascular death (pinteraction = 0.65). Treatment effects of dapagliflozin on the primary outcome were, however, consistent when assessed across the modified Heart Failure Collaboratory Medical Therapy Score integrating both therapeutic use and dosing (pinteraction = 0.39). The use of dapagliflozin was not associated with changes in use or doses of background HF therapies, and among patients on three HF medications at baseline, the addition of dapagliflozin did not lead to higher adverse events.Conclusions
In patients with HFimpEF, the safety and efficacy of dapagliflozin were largely similar by background use and dosing of HF medical therapies. The benefit of dapagliflozin in reducing HF events tended to be greater in those patients on 0-1 medications at baseline. Among patients already on three HF medical therapies, the addition of dapagliflozin was safe without requiring de-escalation of other therapies. 相似文献974.
Alexandra Potvin-Desrochers Alisha Atri Alejandra Martinez Moreno Caroline Paquette 《The European journal of neuroscience》2023,57(1):163-177
Freezing of gait (FOG) is a debilitating motor symptom of Parkinson's disease (PD). Although PD dopaminergic medication (L-DOPA) seems to generally reduce FOG severity, its effect on neural mechanisms of FOG remains to be determined. The purpose of this study was to quantify the effect of L-DOPA on brain resting-state functional connectivity in individuals with FOG. Functional magnetic resonance imaging was acquired at rest in 30 individuals living with PD (15 freezers) in the ON- and OFF- medication state. A seed-to-voxel analysis was performed with seeds in the bilateral basal ganglia nuclei, the thalamus and the mesencephalic locomotor region. In freezers, medication-state contrasts revealed numerous changes in resting-state functional connectivity, not modulated by L-DOPA in non-freezers. In freezers, L-DOPA increased the functional connectivity between the seeds and regions including the posterior parietal, the posterior cingulate, the motor and the medial prefrontal cortices. Comparisons with non-freezers revealed that L-DOPA generally normalizes brain functional connectivity to non-freezers levels but can also increase functional connectivity, possibly compensating for dysfunctional networks in freezers. Our findings suggest that L-DOPA could contribute to a better sensorimotor, attentional, response inhibition and limbic processing to prevent FOG when triggers are encountered but could also contribute to FOG by interfering with the processing capacity of the striatum. This study shows that levodopa taken to control PD symptoms induces changes in functional connectivity at rest, in freezers only. Increases (green) in functional connectivity of GPe, GPi, putamen and thalamus with cognitive, sensorimotor and limbic cortical regions of the Interference model (blue) was observed. Our results suggest that levodopa can normalize connections similar to non-freezers or increases connectivity to compensate for dysfunctional networks. 相似文献
975.
Marcela Chisté Elena Vrotsos Carlos Zamora Antonio Martinez 《Annals of diagnostic pathology》2013,17(3):295-297
Chronic lymphocytic leukemia/small lymphocytic lymphoma is a neoplasm composed of monomorphic small B lymphocytes in the peripheral blood, bone marrow, spleen, and lymph nodes, forming proliferation centers in tissue infiltrates (Muller-Hermelink HK, Montserrat E, Catovsky D, et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma, in Swerdlow SH (ed). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008, pp. 180-182). We report a case of a 77-year-old man with a medical history of chronic lymphocytic leukemia who presented with worsening chest pain over 8 weeks. Imaging studies revealed severe aortic stenosis and moderate mitral regurgitation. He subsequently underwent minimally invasive aortic valve replacement and mitral repair at our institution. Grossly, the specimen consisted of a trileaflet valve with multiple yellow-white focally hemorrhagic and calcified nodules over its surface. Histologically, a lymphocytic infiltrate composed of monotonous small cells with scant cytoplasm was seen as well as calcification and fibrosis. Immunohistochemical stains were positive for CD20, PAX5, CD5, and CD23. To our knowledge, this is the first reported case of an immunohistochemically documented chronic lymphocytic leukemia/small lymphocytic lymphoma to involve a cardiac valve. 相似文献
976.
Edgar Toschi-Dias Ivani C. Trombetta Valdo José Dias da Silva Cristiane Maki-Nunes Maria Janieire N. N. Alves Luciana F. Angelo Felipe X. Cepeda Daniel G. Martinez Carlos Eduardo Negrão Maria Urbana P. B. Rondon 《European journal of applied physiology》2013,113(3):671-679
Previous investigations show that metabolic syndrome (MetSyn) causes sympathetic hyperactivation. Symptoms of anxiety and mood disturbance (AMd) provoke sympatho-vagal imbalance. We hypothesized that AMd would alter even further the autonomic function in patients with MetSyn. Twenty-six never-treated patients with MetSyn (ATP-III) were allocated to two groups, according to the levels of anxiety and mood disturbance: (1) with AMd (MetSyn + AMd, n = 15), and (2) without AMd (MetSyn, n = 11). Ten healthy control subjects were also studied (C, n = 10). AMd was determined using quantitative questionnaires. Muscle sympathetic nerve activity (MSNA, microneurography), blood pressure (oscillometric beat-to-beat basis), and heart rate (ECG) were measured during a baseline 10-min period. Spectral analysis of RR interval and systolic arterial pressure were analyzed, and the power of low (LF) and high (HF) frequency bands were determined. Sympatho-vagal balance was obtained by LF/HF ratio. Spontaneous baroreflex sensitivity (BRS) was evaluated by calculation of α-index. MSNA was greater in patients with MetSyn + AMd compared with MetSyn and C. Patients with MetSyn + AMd showed higher LF and lower HF power compared with MetSyn and C. In addition, LF/HF balance was higher in MetSyn + AMd than in MetSyn and C groups. BRS was decreased in MetSyn + AMd compared with MetSyn and C groups. Anxiety and mood disturbance alter autonomic function in patients with MetSyn. This autonomic dysfunction may contribute to the increased cardiovascular risk observed in patients with mood alterations. 相似文献
977.
978.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
979.
M.B.M. Linhares C.M. Gaspardo L.O. Souza B.O. Valeri F.E. Martinez 《Brazilian journal of medical and biological research》2014,47(6):527-532
Sucrose solution is recommended as relevant pain relief management in neonates duringacute painful procedures; however, only a few studies have analyzed the potentiallyadverse effects of sucrose administration to preterm neonates. The goal of this studywas to examine the potential side effects of sucrose for pain relief in preterminfants, assessing feeding and weight gain during hospitalization and their feedingpatterns postdischarge. The study sample consisted of 43 preterm neonates dividedinto two groups: a sucrose group (SG, n=18) and a control group (CG, n=25) in whichno sucrose was administered. The SG received 0.5 mL/kg 25% oral sucrose for 2 minprior to all acute painful procedures during three consecutive days. A prospectivereview of medical charts was performed for all samples. The study was done prior toimplementation of the institutional sucrose guidelines as a routine service, andfollowed all ethical requirements. There were no statistically significantdifferences between groups in terms of weight gain, length of stay with orogastrictubes, and parenteral feeding. Postdischarge, infant nutritional intake includedfeeding human milk to 67% of the SG and 74% of the CG. There were no statisticallysignificant differences between groups regarding human milk feeding patternspostdischarge. Neonate feeding patterns and weight gain were unaffected following theshort-term use of sucrose for pain relief. 相似文献